Here's Why Juno Therapeutics Stock May Still Be Worth Buying

Here's Why Juno Therapeutics Stock May Still Be Worth Buying

Juno Therapeutics (NASDAQ: JUNO), a clinical-stage adoptive cell therapy company, saw its shares rise by 7% last month, according to data from S&P Global Market Intelligence.

The biotech's shares have been edging higher lately primarily due to Gilead Sciences' (NASDAQ: GILD) $11.9 billion buyout of the rival adoptive cell therapy company Kite Pharma (NASDAQ: KITE), combined with the first-ever regulatory approval of a T cell transfer technology known as chimeric antigen receptor T-cell therapy, or CAR-T for short, with Novartis' Kymriah in late August.

Juno, as a leading CAR-T developer, has clearly been benefiting from this surge in interest from investors, with its shares gaining a healthy 60% in just the past two months. In short, investors appear to be betting that Juno might be the next buyout target by either Gilead or perhaps its main CAR-T development partner, Celgene Corporation. 

Continue reading

Source: Fool.com